top of page

CeleCor

CeleCor Therapeutics

Wondros

2022

Director of Product Design

Summary

CeleCor Therapeutics has developed a revolutionary new first-response therapy for heart attack patients. In its 3rd Phase of clinical trials, zalunfiban is showing great promise for FDA approval.

This site was developed to showcase how zalunfiban works and allow potential investors and therapy advocates to download a product backgrounder, inciting the interest of potential buyers of the technology.

50% of heart-attack deaths occur before a patient reaches the hospital, CeleCor is fighting to change that.

bottom of page